Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 4Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Lymphoproliferative Disorders 2Glioma 2Melanoma 1Locally Advanced Thyroid Gland Carcinoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

Radiotherapy 3Nivolumab 3pembrolizumab 2Temozolomide 2Surveys and Questionnaires 2Paclitaxel 2ONC206 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Etoposide 2Cyclophosphamide 2Carboplatin 2Biopsy 2regorafenib 1pegfilgrastim 1mirdametinib 1lutetium Lu 177 dotatate 1fludarabine 1etoposide phosphate 1entrectinib 1entinostat 1elacestrant 1decitabine and cedazuridine drug combination 1cabozantinib 1amino-acid, glucose, and electrolyte solution 1alectinib 1aflibercept 1abemaciclib 1Topotecan 1Tissue Banks 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Central Nervous System Neoplasms × entrectinib × Clear all
NCT06528691 2026-05-13

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

St. Jude Children's Research Hospital

Phase 2 Recruiting
52 enrolled
CNS

Glioma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡